Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talazoparib and decitabine in AML
NCT02878785Phase 2Completed
- Sponsor
- University of Maryland, Baltimore
- Start
- Aug 2016
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of talazoparib in acute myeloid leukemia (AML), sponsored by University of Maryland, Baltimore. Started Aug 2016; status: completed.
02
Drugs
talazoparib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02878785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02878785.